Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Rhea-AI Summary

Talphera (NASDAQ: TLPH), a specialty pharmaceutical company specializing in innovative therapies for medically supervised settings, has scheduled its first quarter 2025 financial results announcement and corporate update for Wednesday, May 14, 2025. The company will release its financial results after market close, followed by a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time.

Investors can access the webcast through Talphera's website or join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using conference ID 58894. A replay of the webcast will be available on the company's website for 90 days following the event.

SAN MATEO, Calif., May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2025 financial results after market close on Wednesday, May 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 58894.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-first-quarter-financial-results-and-corporate-update-call-and-webcast-on-wednesday-may-14-2025-302448966.html

SOURCE Talphera, Inc.

FAQ

When will Talphera (TLPH) release its Q1 2025 earnings?

Talphera will release its Q1 2025 earnings after market close on Wednesday, May 14, 2025.

How can investors join Talphera's Q1 2025 earnings call?

Investors can join via webcast on Talphera's website or by calling 1-800-836-8184 (North America) or 1-646-357-8785 (international) with conference ID 58894.

What time is Talphera's Q1 2025 earnings call?

The earnings call is scheduled for 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on May 14, 2025.

How long will Talphera's Q1 2025 earnings webcast replay be available?

The webcast replay will be available on Talphera's website for 90 days following the event.